Humanized CC chemokine receptor 4 (CCR4) antibodies and methods of use thereof
The present invention provides humanized monoclonal antibodies, bi-specific antibodies, antibody conjugates, and fusion proteins that bind to the chemokine receptor CCR4. This antibody is derived from CCR4-IgG1 and recognizes the same epitope. This antibody contains either an IgG4 or a stabilized IgG4 in order to improve binding efficiency and reduce in vivo Fab arm exchange. Binding of the antibodies disclosed herein to CCR4 inhibits ligand-mediated activities and is used to treat symptoms of cancer.
1. A nucleic acid encoding an isolated humanized monoclonal antibody that binds to the human CC chemokine receptor 4 (CCR4) and has an IgG4 heavy chain constant region, wherein the antibody comprises:
a heavy chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO: 9, a CDR 2 comprising amino acid sequence SEQ ID NO:11, and a CDR 3 comprising amino acid sequence SEQ ID NO:13; and
a light chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO:10, a CDR 2 comprising amino acid sequence SEQ ID NO:12, and a CDR 3 comprising amino acid sequence SEQ ID NO:14;
a heavy chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO: 33, a CDR 2 comprising amino acid sequence SEQ ID NO: 11, and a CDR 3 comprising amino acid sequence SEQ ID NO:35; and
a light chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO: 10, a CDR 2 comprising amino acid sequence SEQ ID NO: 12, and a CDR 3 comprising amino acid sequence SEQ ID NO:40;
a heavy chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO:33, a CDR 2 comprising amino acid sequence SEQ ID NO:11, and a CDR 3 comprising amino acid sequence SEQ ID NO:36; and
a light chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO:10, a CDR 2 comprising amino acid sequence SEQ ID NO:12, and a CDR 3 comprising amino acid sequence SEQ ID NO:41; or
a heavy chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO: 31, a CDR 2 comprising amino acid sequence SEQ ID NO:11, and a CDR 3 comprising amino acid sequence SEQ ID NO:13; and
a light chain with three CDRs comprising a CDR1 comprising amino acid sequence SEQ ID NO:10, a CDR 2 comprising amino acid sequence SEQ ID NO:12, and a CDR 3 comprising amino acid sequence SEQ ID NO:38; and
a heavy chain constant region comprising the amino acid sequence of SEQ ID NO: 6 or SEQ ID: 8, and wherein the antibody modulates regulatory T cell recruitment without inducing T lymphocyte depletion.
2. The nucleic acid of claim 1 , wherein the isolated humanized monoclonal antibody comprises
a variable heavy chain region (V H ) comprising the amino acid sequence of SEQ ID NO: 2 and a variable light chain region (V L ) comprising the amino acid sequence of SEQ ID NO: 4;
a variable heavy chain region (V H ) comprising the amino acid sequence of SEQ ID NO: 20 and a variable light chain region (V L ) comprising the amino acid sequence of SEQ ID NO: 22;
a variable heavy chain region (V H ) comprising the amino acid sequence of SEQ ID NO: 24 and a variable light chain region (V L ) comprising the amino acid sequence of SEQ ID NO: 25; or
a variable heavy chain region (V H ) comprising the amino acid sequence of SEQ ID NO: 44 and a variable light chain region (V L ) comprising the amino acid sequence of SEQ ID NO: 46; and
the heavy chain constant region comprises SEQ ID NO: 6 or SEQ ID: 8.
3. The nucleic acid of claim 1 , wherein said antibody has a binding affinity of about 1.5 nM −1 or less.
4. The nucleic acid according to claim 1 , wherein the antibody is linked to a therapeutic agent.
5. The nucleic acid of claim 4 , wherein said therapeutic agent is a toxin, a radiolabel, a siRNA, a small molecule, or a cytokine.
6. The nucleic acid of claim 5 , wherein said cytokine is IL-2 or TGF-beta.
7. The nucleic acid of claim 1 , wherein the antibody comprises a bi-specific antibody comprising the isolated humanized monoclonal antibody of claim 1 or 2 that binds to the human CC chemokine receptor 4 (CCR4) and an antibody that immunospecifically binds to a second antigen.
8. The nucleic acid of claim 7 , wherein the second antigen is a tumor associated antigen or a T-cell function modulating molecule.
9. The nucleic acid of claim 8 , wherein the tumor associated antigen is CA-IX, ErbB2 or HVEM.
10. The nucleic acid of claim 8 , wherein the T-cell function modulating molecule is PD-L1, GITR, IL21, IL21R, CD160, TIM3, LAG3 or GALS.
11. A cell comprising the nucleic acid of claim 1 .
12. A method of inhibiting the migration of regulatory T-cells (Tregs) in a subject by administering to said subject the nucleic acid of claim 1 .
13. A method of claim 12 , wherein lymphocytes are not depleted.
14. A method of claim 12 , wherein effector T-cells are not depleted.
15. A method of claim 12 , wherein Tregs are not depleted.
16. A method of augmenting an immune response to an antigen in a subject comprising administering to the subject the nucleic acid of claim 1 .
17. The method of claim 16 , wherein said antigen is a viral antigen, a bacterial antigen or a tumor associated antigen.
18. The method of claim 16 , wherein said administration of said nucleic acid causes an increase in antigen specific T-cell activity.
19. The method of claim 16 , wherein said administration of said nucleic acid causes an increase in T-cell proliferation.
20. The method of claim 16 , wherein effector T-cells are augmented.
21. A method of reversing regulatory T cell-mediated suppression of effector T cell proliferation comprising contacting a T cell with the antibody encoded by the nucleic acid of claim 1 .
22. A method of treating or alleviating a symptom of cancer, comprising administering to a subject in need thereof a composition comprising the nucleic acid according to claim 1 .
23. The method of claim 22 , wherein said cancer is a solid cancer or a hematologic cancer.
24. The method of claim 23 , wherein said hematologic cancer is cutaneous T-cell Lymphoma (CTCL), mycosis fungoides (MF), primary cutaneous anaplastic large cell Lymphoma (cutaneous ALCL), Sezary syndrome, or adult T cell Leukemia/Lymphoma (ATLL).
25. The method of claim 23 , wherein the cancer is a solid cancer or a cancer that overexpresses CA IX, PD-L1, or HVEM.
26. The method of claim 23 , were said solid cancer is renal cell carcinoma, breast cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, cervical cancer, brain cancer, liver cancer, pancreatic cancer, kidney or stomach cancer.
27. A vector comprising the nucleic acid of claim 1 .
28. An isolated cell comprising the vector of claim 27 .
29. The nucleic acid of claim 1 , wherein the nucleic acid comprises SEQ ID NO: 1 and SEQ ID NO: 3; SEQ ID NO: 19 and SEQ ID NO: 21; SEQ ID NO: 23 and SEQ ID NO: 25; or SEQ ID NO: 43 and SEQ ID NO: 45; and wherein the nucleic acid further comprises SEQ ID NO: 5 or SEQ ID NO: 7.
30. A nucleic acid comprising the nucleic acid sequence of SEQ ID NOs: 1 and 3, SEQ ID NOs: 19 and 21, SEQ ID NOs: 23 and 25, or SEQ ID NOs: 43 and 45, wherein the nucleic acid further comprises SEQ ID NO: 5 or SEQ ID NO: 7.
31. A vector comprising the nucleic acid of claim 30 .
32. An isolated cell comprising the vector of claim 31 .